GlassScriptPhysician profile
Andrew Herrin
NPI 1407912413
$1,811.41
in general payments reported to CMS, 2019-2025
30 companies · $208 in 2025
The $208 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.89 · 2020: $294 · 2021: $346 · 2022: $252 · 2023: $240 · 2024: $409 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $361.86 | 2021-2024 | Veozah |
| Abbvie INC. | $286.38 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $254.96 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $83.65 | 2023-2025 | Myfembree |
| Amgen INC. | $77.65 | 2019-2024 | Evenity, Prolia |
| Mayne Pharma Commercial LLC | $72.32 | 2021-2025 | |
| Organon LLC | $57.09 | 2022-2024 | |
| Hologic Sales and Service, LLC | $56.53 | 2021-2025 | Aptima |
| Coopersurgical, INC. | $50.37 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Caldera Medical, INC | $47.59 | 2021 | |
| Abbott Laboratories | $46.30 | 2021 | |
| Biogen, INC. | $44.53 | 2025 | Zurzuvae |
| Therapeuticsmd, INC. | $43.20 | 2020-2022 | |
| Avion Pharmaceuticals | $28.19 | 2022 | |
| Lupin INC. | $27.60 | 2020-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Innovation Technologies INC | $26.42 | 2025 | Irrisept |
| Pfizer INC. | $26.06 | 2020 | |
| Viiv Healthcare Company | $23.66 | 2023 | Apretude |
| Vertex Pharmaceuticals Incorporated | $22.22 | 2024 | |
| Ethicon US, LLC | $21.48 | 2020 | |
| Millicent US INC | $19.88 | 2024 | Intrarosa, Femring |
| Roche Diagnostics Corporation | $18.26 | 2021 | |
| Amneal Pharmaceuticals LLC | $17.27 | 2022 | |
| Scynexis, INC. | $16.64 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.94 | 2021 | |
| Smith+Nephew, INC. | $14.76 | 2022 | |
| Agile Therapeutics, INC. | $13.38 | 2022 | |
| Merck Sharp & Dohme LLC | $12.82 | 2021 | |
| Idorsia Pharmaceuticals US INC | $12.82 | 2023 | Quviviq |
| Minerva Surgical, INC | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Herrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.